Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

MycN sensitizes neuroblastoma cells for drug-induced apoptosis

Abstract

Amplification of the MYCN gene is found in a large proportion of neuroblastoma and considered as an adverse prognostic factor. To investigate the effect of ectopic MycN expression on the susceptibility of neuroblastoma cells to cytotoxic drugs we used a human neuroblastoma cell line harboring tetracycline-controlled expression of MycN. Neither conditional expression of MycN alone nor low drug concentrations triggered apoptosis. However, when acting in concert, MycN and cytotoxic drugs efficiently induced cell death. Apoptosis depended on mitochondrial permeability transition and activation of caspases, since the mitochondrion-specific inhibitor bongkrekic acid and the caspase inhibitor ZVAD-fmk almost completely abrogated apoptosis. Loss of mitochondrial transmembrane potential and release of cytochrome c from mitochondria preceded activation of caspase-8 and caspase-3 and cleavage of PARP. CD95 expression was upregulated by treatment with cytotoxic drugs, while MycN cooperated with cytotoxic drugs to increase sensitivity to CD95-induced apoptosis and enhancing CD95-L expression. MycN overexpression and cytotoxic drugs also synergized to induce p53 and Bax protein expression, while Bcl-2 and Bcl-XL protein levels remained unchanged. Since amplification of MYCN is usually associated with a poor prognosis, these findings suggest that dysfunctions in apoptosis pathways may be a mechanism by which MycN-induced apoptosis of neuroblastoma cells is inhibited.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

Abbreviations

BA:

bongkrekic acid

CD95-L:

CD95 ligand

DiOC6(3):

3,3′-dihexyloxacarbocyanide iodide

Doxo:

Doxorubicin

ECL:

enhanced chemiluminescence

FACS:

fluorescence-activated cell-sorting

ICE:

interleukin 1β-converting enzyme

ΔΨm:

mitochondrial transmembrane potential

PARP:

poly(ADP-ribose) polymerase

Z-VAD.fmk:

benzyloxycarbonyl-Val-Ala-Asp-fluoromethyl ketone

References

  • Bargou RC, Wagener C, Bommert K, Mapara MY, Daniel PT, Arnold W, Dietel M, Guski H, Feller A, Royer HD and Dörken B. . 1996 J. Clin. Invest. 96: 2651–2659.

    Article  CAS  Google Scholar 

  • Berthold F. . 1990 Overview: Biology of Neuroblastoma. C Pochedly (ed.).. Boca Raton, Florida: CRC Press. pp. 1–30.

    Google Scholar 

  • Bissonette RP, Echeverri F, Mahboudi A and Green DR. . 1992 Nature 359: 552–556.

    Article  CAS  Google Scholar 

  • Dong J, Naito M and Tsuruo T. . 1997 Oncogene 15: 639–647.

    Article  CAS  Google Scholar 

  • Eischen CM, Kottke TJ, Martins LM, Basi GS, Tun JS, Earnshaw WC, Leibson PJ and Kaufmann SH. . 1997 Blood 90: 935–943.

  • Faris N, Kokot K, Latinis S, Kasibhatla DR, Green GA, Koretzky and Nel A. . 1998 J. Immunol. 160: 134–144.

  • Fisher DE. . 1994 Cell 78: 539–542.

    Article  CAS  Google Scholar 

  • Friesen C, Herr I, Krammer PH and Debatin KM. . 1996 Nat. Med. 2: 574–577.

  • Fulda S, Sieverts H, Friesen C, Herr I and Debatin KM. . 1997a Cancer Res. 57: 3823–3829.

  • Fulda S, Friesen C, Los M, Scaffidi C, Mier W, Benedict M, Nuñez G, Krammer PH, Peter ME and Debatin KM. . 1997b Cancer Res. 57: 4956–4964.

  • Fulda S, Los M, Friesen C and Debatin KM. . 1998a Int. J. Cancer 76: 105–114.

    Article  CAS  Google Scholar 

  • Fulda S, Scaffidi C, Pietsch T, Krammer PH, Peter ME and Debatin KM. . 1998b Cell Death Differ. in press.

  • Henriksson M and Lüscher B. . 1996 Adv. Cancer Res., 68 109–182.

  • Hermeking H and Eick D. . 1994 Science 265: 2091–2093.

    Article  CAS  Google Scholar 

  • Herr I, Boehler T, Wilhelm D, Angel P and Debatin KM. . 1997 EMBO J. 16: 6200–6208.

  • Hueber AO, Zörnig M, Lyon D, Suda T, Nagata S and Evan GI. . 1997 Science 278: 1305–1309.

    Article  CAS  Google Scholar 

  • Janicke RU, Lee FH and Porter AG. . 1994 Mol. Cell. Biol. 14: 5661–5670.

    Article  Google Scholar 

  • Kischkel FC, Hellbrandt S, Behrmann I, Germer M, Pawlita M, Krammer PH and Peter ME. . 1995 EMBO J. 14: 5579–5588.

  • Klefstrom J, Vastrik I, Saksela E, Valle J, Eilers M and Alitalo K. . 1994 EMBO J. 13: 5442–5450.

  • Klefstrom J, Arighi E, Littlewood T, Jaattela M, Saksela S, Evan GI and Alitalo K. . 1997 EMBO J. 16: 7382–7392.

  • Kroemer G. . 1997a Nat. Med. 3: 614–620.

  • Kroemer G, Zamzami N and Susin SA. . 1997b Immunol. Today 18: 44–51.

  • Los M, Van de Craen M, Penning LC, Schenk H, Westendorp M, Baeuerle PA, Droege W, Krammer PH, Fiers W and Schulze-Osthoff K. . 1995 Nature 375: 81–83.

    Article  CAS  Google Scholar 

  • Lutz W, Stöhr M, Schürmann J, Wenzel A, Löhr A and Schwab M. . 1996 Oncogene 13: 803–812.

  • Lutz W, Fulda S, Jeremias I, Debatin KM and Schwab M. . 1998 Oncogene 17: 339–346.

    Article  CAS  Google Scholar 

  • Medema JP, Scaffidi C, Kischkel FC, Shevchenko A, Mann M, Krammer PH and Peter ME. . 1997 EMBO J. 16: 2794–2804.

  • Miyashita T and Reed JC. . 1995 Cell 80: 293–299.

    Article  Google Scholar 

  • Muzio M, Chinnaiyan AM, Kischkel FC, O'Rourke K, Shevchenko A, Ni J, Scaffidi C, Bretz JD, Zhang M, Gentz R, Mann M, Krammer PH, Peter ME and Dixit VM. . 1996 Cell 85: 817–827.

    Article  CAS  Google Scholar 

  • Müller M, Strand S, Hug H, Heinemann EM, Walczak H, Hofmann WJ, Stremmel W, Krammer PH and Galle PR. . 1997 J. Clin. Invest. 99: 403–413.

    Article  Google Scholar 

  • Nagata S. . 1997 Cell 88: 355–365.

    Article  CAS  Google Scholar 

  • Nicoletti I, Migliorati G, Pagliacci MC, Grignani F and Riccardi C. . 1991 J. Immunol. Methods 139: 271–279.

  • Niimi S, Nakagawa K, Yokota J, Tsunokawa Y, Nishio K, Terashima Y, Shibuya M, Terada M and Saijo N. . 1991 Br. J. Cancer 63: 237–241.

  • Oehm A, Behrmann I, Falk W, Pawlita M, Maier G, Klas C, Li-Weber M, Richards S, Dhein J, Trauth BC, Ponstingl H and Krammer PH. . 1992 J. Biol. Chem. 267: 10709–10715.

  • Packham G, Porter CW and Cleveland JL. . 1996 Oncogene 13: 461–469.

  • Pastorino JG, Chen ST, Tafani M, Snyder JW and Farber JL. . 1998 J. Biol. Chem. 273: 7770–7775.

    Article  CAS  Google Scholar 

  • Peter ME, Kischkel FC, Hellbrandt S, Chinnaiyan AM, Krammer PH and Dixit VM. . 1996 Cell Death Differ. 3: 161–170.

  • Scaffidi C, Fulda S, Li F, Friesen C, Srinivasan A, Tomaselli KJ, Debatin KM, Krammer PH and Peter ME. . 1998 EMBO J. 17: 1675–1687.

  • Scaffidi C, Medema JP, Krammer PH and Peter ME. . 1997 J. Biol. Chem. 272: 26953–26958.

    Article  CAS  Google Scholar 

  • Schwab M, Corvi R and Amler L. . 1995 The Neuroscientist 1: 277–285.

    Article  CAS  Google Scholar 

  • Schweigerer L, Breit S, Wenzel A, Tsunamoto K, Ludwig R and Schwab M. . 1990 Cancer Res. 50: 4411–4416.

  • Susin SA, Zamzami N, Castedo M, Daugas E, Wang HG, Geley S, Fassy F, Reed JC and Kroemer G. . 1997 J. Exp. Med. 186: 25–37.

  • Trauth BC, Klas C, Peter AMJ, Matz S, Möller P, Falk W, Debatin KM and Krammer PH. . 1989 Science 245: 301–305.

    Article  CAS  Google Scholar 

  • Villunger A, Egle A, Kos M, Hartmann B, Geley S, Kofler R and Greil R. . 1997 Cancer Res. 57: 3331–3334.

  • Weiss WA, Aldape K, Mohapatra G, Feuerstein BG and Bishop JM. . 1997 EMBO J. 16: 12985–12995.

  • Wolter KG, Hsu YT, Smith CL, Nechushtan A, Xi XG and Youle RJ. . 1997 J. Cell Biol. 139: 1281–1292.

  • Yeh WC, Pompa JL, McCurrach ME, Shu HB, Elia AJ, Shahinian A, Ng M, Wakeham A, Khoo W, Mitchell K, El-Deiry WS, Lowe SW, Goeddel DV and Mak TW. . 1998 Science 279: 1954–1958.

  • Yu K, Ravera CP, Chen YNP and McMahon G. . 1997 Cell Growth Differ. 8: 731–742.

  • Zamzami N, Susin SA, Marchetti P, Hirsch T, Gomez-Monterrey I, Castedo M and Kroemer G. . 1996 J. Exp. Med. 183: 1533–1542.

  • Zörnig M, Grzeschiczek A, Kowalski MB, Hartmann KU and Möröy T. . 1995a Oncogene 10: 2397–2401.

  • Zörnig M, Busch G, Beneke R, Gulbins E, Lang F, Ma A, Korsmeyer S and Möröy T. . 1995b Oncogene 11: 2165–2174.

Download references

Acknowledgements

This work has been partially supported by grants from the Deutsche Forschungsgemeinschaft, the Bundesministerium für Forschung and Technologie, Bonn, the Tumor Center Heidelberg/Mannheim, The Deutsche Leukämieforschungshilfe (to K-MD), the Dr Mildred Scheel Stiftung and the Fördergemeinschaft Kinderkrebs-Neuroblastom-Forschung e.V. (to MS).

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fulda, S., Lutz, W., Schwab, M. et al. MycN sensitizes neuroblastoma cells for drug-induced apoptosis. Oncogene 18, 1479–1486 (1999). https://doi.org/10.1038/sj.onc.1202435

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1202435

Keywords

This article is cited by

Search

Quick links